SG11201608729RA - Membrane-adherent self-assembled systems for treatment of ocular disorders - Google Patents
Membrane-adherent self-assembled systems for treatment of ocular disordersInfo
- Publication number
- SG11201608729RA SG11201608729RA SG11201608729RA SG11201608729RA SG11201608729RA SG 11201608729R A SG11201608729R A SG 11201608729RA SG 11201608729R A SG11201608729R A SG 11201608729RA SG 11201608729R A SG11201608729R A SG 11201608729RA SG 11201608729R A SG11201608729R A SG 11201608729RA
- Authority
- SG
- Singapore
- Prior art keywords
- membrane
- treatment
- ocular disorders
- assembled systems
- adherent self
- Prior art date
Links
- 208000022873 Ocular disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461987012P | 2014-05-01 | 2014-05-01 | |
PCT/US2015/028748 WO2015168523A1 (en) | 2014-05-01 | 2015-05-01 | Membrane-adherent self-assembled systems for treatment of ocular disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201608729RA true SG11201608729RA (en) | 2016-11-29 |
Family
ID=54359368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201608729RA SG11201608729RA (en) | 2014-05-01 | 2015-05-01 | Membrane-adherent self-assembled systems for treatment of ocular disorders |
Country Status (12)
Country | Link |
---|---|
US (2) | US9901544B2 (en) |
EP (1) | EP3137481B1 (en) |
JP (1) | JP6452725B2 (en) |
KR (1) | KR101890503B1 (en) |
CN (1) | CN106459137B (en) |
AU (2) | AU2015252908B2 (en) |
CA (1) | CA2946373C (en) |
ES (1) | ES2924768T3 (en) |
MY (1) | MY193694A (en) |
NZ (1) | NZ725028A (en) |
SG (1) | SG11201608729RA (en) |
WO (1) | WO2015168523A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20170147B1 (en) * | 2016-07-07 | 2021-08-17 | Salvat Lab Sa | Ophthalmic composition comprising castor oil and medium chain triglyceride |
WO2018230711A1 (en) | 2017-06-16 | 2018-12-20 | 学校法人同志社 | Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
EP3639855A4 (en) * | 2017-06-16 | 2021-03-17 | The Doshisha | COMPOUNDS HAVING A CASPASE-INHIBITING EFFECT, PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF CORNEAL DOTHELIC SYMPTOMS, DISORDERS OR DISEASES AND USE OF THIS PHARMACEUTICAL AGENT |
JP6931493B2 (en) * | 2017-06-22 | 2021-09-08 | ヨンスン ファイン ケミカル カンパニー,リミテッド | Eye drop composition for glaucoma treatment |
US11129862B2 (en) * | 2017-08-30 | 2021-09-28 | Johnson & Johnson Consumer Inc. | Ophthalmic compositions |
US11000530B2 (en) * | 2017-09-01 | 2021-05-11 | Murray And Poole Enterprises Ltd | Methods and compositions for the treatment of ophthalmic conditions |
JP7056480B2 (en) * | 2017-09-08 | 2022-04-19 | ライオン株式会社 | Ophthalmic composition and tear oil layer stabilizer |
CN109316440B (en) * | 2018-09-29 | 2020-12-29 | 华中科技大学 | A kind of temperature-sensitive liquid crystal nano-hydrogel and its preparation method and application |
BR112021007140A2 (en) * | 2018-10-24 | 2021-07-20 | Ferring B.V. | mucoadhesive pharmaceutical compositions of corticosteroids |
GB201818043D0 (en) * | 2018-11-05 | 2018-12-19 | Waterford Institute Of Tech | Artifical Tears |
US20210353554A1 (en) * | 2020-05-18 | 2021-11-18 | Max Biology Co. Ltd. | Lipid-polymer compositions and methods of use |
US12102632B2 (en) | 2020-08-26 | 2024-10-01 | Somerset Therapeutics, Llc | Quinolone dispersions |
US11382910B2 (en) * | 2020-08-26 | 2022-07-12 | Somerset Therapeutics, Llc. | Loteprednol and moxifloxacin compositions and methods |
WO2022077060A1 (en) * | 2020-10-13 | 2022-04-21 | University Of South Australia | Antimicrobial compositions and methods of use |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6716830B2 (en) * | 1998-09-30 | 2004-04-06 | Alcon, Inc. | Ophthalmic antibiotic compositions containing moxifloxacin |
PE20020146A1 (en) * | 2000-07-13 | 2002-03-31 | Upjohn Co | OPHTHALMIC FORMULATION INCLUDING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR |
JP4049216B2 (en) * | 2003-05-09 | 2008-02-20 | ポーラ化成工業株式会社 | Formulation with liquid crystal structure |
US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US20050235740A1 (en) * | 2004-04-27 | 2005-10-27 | Guido Desie | Method to improve the quality of dispersion formulations |
WO2006009825A1 (en) * | 2004-06-17 | 2006-01-26 | Virun, Inc. | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents |
US20080145430A1 (en) * | 2004-12-08 | 2008-06-19 | Santipharp Panmai | Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor |
CN101137369A (en) * | 2005-02-09 | 2008-03-05 | 马库赛特公司 | Formulations for ocular treatment |
US8906392B2 (en) | 2005-12-16 | 2014-12-09 | University Of Kansas | Nanocluster compositions and methods |
WO2008011836A2 (en) * | 2006-07-25 | 2008-01-31 | Osmotica Corp. | Ophthalmic solutions |
JP2010064995A (en) * | 2008-09-12 | 2010-03-25 | Nikko Chemical Co Ltd | Anti-inflammatory analgesic composition for external application |
US8703922B2 (en) * | 2009-12-25 | 2014-04-22 | Chemgenesis Incorporated | Low-viscosity liquid crystal compound |
CN101773670A (en) * | 2009-12-29 | 2010-07-14 | 中山大学 | Liquid crystal medicine carrier |
JP2012017318A (en) * | 2010-06-07 | 2012-01-26 | Nikko Chemical Co Ltd | Liquid crystal and skin external preparation containing the same |
US8772273B2 (en) * | 2011-10-04 | 2014-07-08 | Quretino Therapeutics, Inc. | Formulations and uses of retinoic acid receptor selective agonists |
HK1208161A1 (en) * | 2012-05-03 | 2016-02-26 | Alcon Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
WO2013169647A1 (en) * | 2012-05-08 | 2013-11-14 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
-
2015
- 2015-05-01 ES ES15785661T patent/ES2924768T3/en active Active
- 2015-05-01 US US15/308,000 patent/US9901544B2/en active Active
- 2015-05-01 KR KR1020167030513A patent/KR101890503B1/en active Active
- 2015-05-01 EP EP15785661.8A patent/EP3137481B1/en active Active
- 2015-05-01 JP JP2016565482A patent/JP6452725B2/en active Active
- 2015-05-01 MY MYPI2016703941A patent/MY193694A/en unknown
- 2015-05-01 SG SG11201608729RA patent/SG11201608729RA/en unknown
- 2015-05-01 CN CN201580019868.9A patent/CN106459137B/en active Active
- 2015-05-01 CA CA2946373A patent/CA2946373C/en active Active
- 2015-05-01 WO PCT/US2015/028748 patent/WO2015168523A1/en active Application Filing
- 2015-05-01 NZ NZ725028A patent/NZ725028A/en unknown
- 2015-05-01 AU AU2015252908A patent/AU2015252908B2/en active Active
-
2018
- 2018-02-27 US US15/906,352 patent/US10603273B2/en active Active
- 2018-03-06 AU AU2018201596A patent/AU2018201596B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP6452725B2 (en) | 2019-01-16 |
MY193694A (en) | 2022-10-25 |
AU2015252908B2 (en) | 2017-12-07 |
JP2017514843A (en) | 2017-06-08 |
CN106459137A (en) | 2017-02-22 |
ES2924768T3 (en) | 2022-10-10 |
CN106459137B (en) | 2019-04-12 |
NZ725028A (en) | 2019-01-25 |
US10603273B2 (en) | 2020-03-31 |
AU2015252908A1 (en) | 2016-10-27 |
CA2946373A1 (en) | 2015-11-05 |
KR101890503B1 (en) | 2018-08-21 |
EP3137481A1 (en) | 2017-03-08 |
EP3137481A4 (en) | 2017-12-27 |
KR20160147784A (en) | 2016-12-23 |
US20180185275A1 (en) | 2018-07-05 |
AU2018201596B2 (en) | 2020-02-06 |
WO2015168523A1 (en) | 2015-11-05 |
US9901544B2 (en) | 2018-02-27 |
EP3137481B1 (en) | 2022-07-06 |
CA2946373C (en) | 2018-07-31 |
US20170049697A1 (en) | 2017-02-23 |
AU2018201596A1 (en) | 2018-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL288712B1 (en) | Methods for the treatment of abnormal involuntary movement disorders | |
IL248732B (en) | Compounds for treating ophthalmic diseases and disorders | |
SG11201608729RA (en) | Membrane-adherent self-assembled systems for treatment of ocular disorders | |
IL247515A0 (en) | Cenicriviroc for the treatment of fibrosis | |
EP3191185A4 (en) | Device for targeted treatment of dermastoses | |
EP3119911A4 (en) | Methods for treating neurological disorders | |
IL249502B (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies | |
GB201408387D0 (en) | Treatment of respiratory disorders | |
SG11201708181RA (en) | Methods for the treatment of inflammatory disorders | |
GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
EP3145525A4 (en) | Use of microperoxidases for the treatment of carboxyhemoglobinemia | |
EP3200795A4 (en) | Use of agents for treating fat-related disorders | |
PL2937084T3 (en) | Method for the treatment of hypercholesterolemia | |
SI3903774T1 (en) | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases | |
HK40035958B (en) | Apparatus for treatment of brain disorders | |
HK40088295A (en) | Treatment of immune disorders | |
HK40087941A (en) | Methods for the treatment of abnormal involuntary movement disorders | |
GB201602784D0 (en) | New treatment of CFTR-related disorders | |
GB201506228D0 (en) | Methods For The Treatment Of Cardivascular Disorders | |
GB201521543D0 (en) | Methods for the treatment of inflammatory disorders | |
GB201513993D0 (en) | Methods for the treatment of inflammatory disorders | |
GB201513345D0 (en) | Methods for the treatment of Inflammatory disorders | |
EP3177316A4 (en) | Method for preventing or treating ocular disorders | |
AU2014902194A0 (en) | Treatment of immune disorders | |
GB201507113D0 (en) | Methods for the treatment of inflammatory disorders |